title: A novel rabies vaccine based-on toll-like receptor 3 (TLR3) agonist PIKA adjuvant exhibiting excellent safety and efficacy in animal studies.
abstract: Vaccination alone is not sufficiently effective to protect human from post-exposure rabies virus infection due to delayed generation of rabies virus neutralizing antibodies and weak cellular immunity. Therefore, it is vital to develop safer and more efficacious vaccine against rabies. PIKA, a stabilized chemical analog of double-stranded RNA that interacts with TLR3, was employed as adjuvant of rabies vaccine. The efficacy and safety of PIKA rabies vaccine were evaluated. The results showed that PIKA rabies vaccine enhanced both humoral and cellular immunity. After viral challenge, PIKA rabies vaccine protected 70-80% of animals, while the survival rate of non-adjuvant vaccine group (control) was 20-30%. According to the results of toxicity tests, PIKA and PIKA rabies vaccine are shown to be well tolerated in mice. Thus, this study indicates that PIKA rabies vaccine is an effective and safe vaccine which has the potential to develop next-generation rabies vaccine and encourage the start of clinical studies.
authors.affiliation: Yisheng Biopharma. Co., Ltd., Beijing, China.
authors.forename: Yi
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: Academy of Military Medical Sciences, Changchun, China.
authors.forename: Shoufeng
authors.initials: S
authors.lastname: Zhang
authors.affiliation: National Center for Safety Evaluation of Drugs, Beijing, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Li
authors.affiliation: Beijing Institute for Drug Control, Beijing, China.
authors.forename: Yuchi
authors.initials: Y
authors.lastname: Hu
authors.affiliation: Beijing Institute for Drug Control, Beijing, China.
authors.forename: Jinyan
authors.initials: J
authors.lastname: Zhao
authors.affiliation: Yisheng Biopharma. Co., Ltd., Beijing, China.
authors.forename: Fang
authors.initials: F
authors.lastname: Liu
authors.affiliation: Yisheng Biopharma. Co., Ltd., Beijing, China.
authors.forename: Haixiang
authors.initials: H
authors.lastname: Lin
authors.affiliation: Yisheng Biopharma. Co., Ltd., Beijing, China.
authors.forename: Yuan
authors.initials: Y
authors.lastname: Liu
authors.affiliation: Yisheng Biopharma. Co., Ltd., Beijing, China.
authors.forename: Liliang
authors.initials: L
authors.lastname: Wang
authors.affiliation: Yisheng Biopharma. Co., Ltd., Beijing, China.
authors.forename: Shu
authors.initials: S
authors.lastname: Xu
authors.affiliation: Academy of Military Medical Sciences, Changchun, China. Electronic address: ronglianghu@hotmail.com.
authors.forename: Rongliang
authors.initials: R
authors.lastname: Hu
authors.affiliation: Yisheng Biopharma. Co., Ltd., Beijing, China. Electronic address: hui.shao@yishengbio.com.
authors.forename: Hui
authors.initials: H
authors.lastname: Shao
authors.affiliation: Yisheng Biopharma. Co., Ltd., Beijing, China. Electronic address: lietao.li@gmail.com.
authors.forename: Lietao
authors.initials: L
authors.lastname: Li
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000276:immunology; D004353:Drug Evaluation, Preclinical; D005260:Female; D006801:Humans; D007111:Immunity, Cellular; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D012330:RNA, Double-Stranded / Q000008:administration & dosage / Q000009:adverse effects / Q000235:genetics / Q000276:immunology*; D011818:Rabies / Q000276:immunology* / Q000517:prevention & control / Q000821:virology; D011819:Rabies Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D011820:Rabies virus / Q000235:genetics / Q000276:immunology*; D051196:Toll-Like Receptor 3 / Q000819:agonists* / Q000276:immunology
chemical_list: D000914:Antibodies, Viral; D012330:RNA, Double-Stranded; D011819:Rabies Vaccines; C495344:TLR3 protein, human; D051196:Toll-Like Receptor 3
keywords: Efficacy; PIKA adjuvant; Rabies vaccine; Safety